对 "口服甘纳可龙治疗 PCDH19 聚集性癫痫的 2 期安慰剂对照临床研究 "的更正 [Epilepsy Res. (2023) 191 107112]。

IF 2 4区医学 Q3 CLINICAL NEUROLOGY

Epilepsy Research Pub Date : 2024-03-12 DOI:10.1016/j.eplepsyres.2024.107342

Joseph Sullivan , Boudewijn Gunning , Muhammad Zafar , Renzo Guerrini , Jozef Gecz , Kristy L. Kolc , Yufan Zhao , Maciej Gasior , Alex A. Aimetti , Debopam Samanta

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Corrigendum to “Phase 2, placebo-controlled clinical study of oral ganaxolone in PCDH19-clustering epilepsy” [Epilepsy Res. (2023) 191 107112]

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Epilepsy Research 医学-临床神经学

CiteScore

0.10

自引率

4.50%

发文量

143

审稿时长

62 days

期刊介绍： Epilepsy Research provides for publication of high quality articles in both basic and clinical epilepsy research, with a special emphasis on translational research that ultimately relates to epilepsy as a human condition. The journal is intended to provide a forum for reporting the best and most rigorous epilepsy research from all disciplines ranging from biophysics and molecular biology to epidemiological and psychosocial research. As such the journal will publish original papers relevant to epilepsy from any scientific discipline and also studies of a multidisciplinary nature. Clinical and experimental research papers adopting fresh conceptual approaches to the study of epilepsy and its treatment are encouraged. The overriding criteria for publication are novelty, significant clinical or experimental relevance, and interest to a multidisciplinary audience in the broad arena of epilepsy. Review articles focused on any topic of epilepsy research will also be considered, but only if they present an exceptionally clear synthesis of current knowledge and future directions of a research area, based on a critical assessment of the available data or on hypotheses that are likely to stimulate more critical thinking and further advances in an area of epilepsy research.